AU2010278302B2 - MUC1 antibodies - Google Patents

MUC1 antibodies Download PDF

Info

Publication number
AU2010278302B2
AU2010278302B2 AU2010278302A AU2010278302A AU2010278302B2 AU 2010278302 B2 AU2010278302 B2 AU 2010278302B2 AU 2010278302 A AU2010278302 A AU 2010278302A AU 2010278302 A AU2010278302 A AU 2010278302A AU 2010278302 B2 AU2010278302 B2 AU 2010278302B2
Authority
AU
Australia
Prior art keywords
antibody
amino acid
cancer
derivative
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010278302A
Other languages
English (en)
Other versions
AU2010278302A1 (en
Inventor
Antje Danielczyk
Steffen Goletz
Uwe Karsten
Renate Stahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AU2010278302A1 publication Critical patent/AU2010278302A1/en
Application granted granted Critical
Publication of AU2010278302B2 publication Critical patent/AU2010278302B2/en
Assigned to DAIICHI SANKYO CO., LTD. reassignment DAIICHI SANKYO CO., LTD. Request for Assignment Assignors: GLYCOTOPE GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2010278302A 2009-07-31 2010-07-30 MUC1 antibodies Active AU2010278302B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23021109P 2009-07-31 2009-07-31
US61/230,211 2009-07-31
EP09009942.5 2009-07-31
EP09009942A EP2281844A1 (en) 2009-07-31 2009-07-31 MUC 1 antibodies
PCT/EP2010/004663 WO2011012309A1 (en) 2009-07-31 2010-07-30 Muc1 antibodies

Publications (2)

Publication Number Publication Date
AU2010278302A1 AU2010278302A1 (en) 2012-02-09
AU2010278302B2 true AU2010278302B2 (en) 2014-12-18

Family

ID=41460131

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010278302A Active AU2010278302B2 (en) 2009-07-31 2010-07-30 MUC1 antibodies

Country Status (17)

Country Link
US (1) US9217038B2 (enExample)
EP (3) EP2281844A1 (enExample)
JP (2) JP5922018B2 (enExample)
KR (1) KR101773506B1 (enExample)
CN (1) CN102574926B (enExample)
AR (1) AR077334A1 (enExample)
AU (1) AU2010278302B2 (enExample)
BR (1) BR112012002226A2 (enExample)
CA (1) CA2768888C (enExample)
CU (1) CU23972B1 (enExample)
EA (1) EA029954B1 (enExample)
IL (1) IL217827A (enExample)
MX (1) MX2012000874A (enExample)
NZ (1) NZ597563A (enExample)
SG (2) SG10201404019XA (enExample)
WO (1) WO2011012309A1 (enExample)
ZA (1) ZA201200166B (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) * 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US8518405B2 (en) * 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
PT2603528T (pt) 2010-08-10 2016-12-01 Glycotope Gmbh Anticorpos glicosilados em fab
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
ES2686313T3 (es) 2011-08-22 2018-10-17 Glycotope Gmbh Microorganismos que portan un antígeno tumoral
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
EP2963126B1 (en) * 2013-03-01 2019-04-03 Saitama Medical University Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism
US10208125B2 (en) * 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2938819A1 (en) 2014-02-06 2015-08-13 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Antibody to mucin 4 (muc4) glycopeptide and uses thereof
US10239950B2 (en) * 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
WO2016026143A1 (en) * 2014-08-22 2016-02-25 Huiru Wang Saccharide-based biomarkers and therapeutics
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
CN116199790A (zh) 2015-02-10 2023-06-02 米纳瓦生物技术公司 人源化抗MUCl*抗体
WO2017139975A1 (en) 2016-02-19 2017-08-24 Huiru Wang Antibodies against n-acetylglucosamine and n-acetyl-galactosamine
TWI780082B (zh) 2016-11-18 2022-10-11 日商安斯泰來製藥股份有限公司 新穎抗人類ＭＵＣ１抗體Ｆａｂ片段
EP3570881A4 (en) * 2017-01-18 2020-08-19 Nanocruise Pharmaceutical Ltd. MONOCLONAL AND HUMANIZED ANTIBODIES DIRECTED AGAINST CANCER GLYCOPEPTIDE
US20190343953A1 (en) 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
WO2018178047A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Multispecific antibody constructs binding to muc1 and cd3
WO2018178046A1 (en) 2017-03-29 2018-10-04 Glycotope Gmbh Humanized anti-cd40 antibodies
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
NZ762505A (en) 2017-09-29 2026-03-27 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
US12605469B2 (en) 2017-10-02 2026-04-21 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
US11161911B2 (en) 2017-10-23 2021-11-02 Go Therapeutics, Inc. Anti-glyco-MUC1 antibodies and their uses
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15
BR112020023420A8 (pt) 2018-05-17 2022-07-05 Astellas Pharma Inc Complexo tendo fragmento fab de anticorpo anti-muc1 humano, peptídeo ligador e/ou ligante
SG11202010496WA (en) 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
CN108982854B (zh) * 2018-06-19 2021-07-27 哈尔滨医科大学 蛋白质muc13在制备诊断肝内胆管癌的试剂中的应用
JP7541930B2 (ja) * 2018-06-29 2024-08-29 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｍｕｃ１抗体およびその使用
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN113631229B (zh) 2019-03-25 2025-09-23 第一三共株式会社 抗体－吡咯并苯并二氮杂卓衍生物偶联物
CA3139180A1 (en) 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
WO2023121448A1 (en) * 2021-12-21 2023-06-29 Merus N.V. Binding domains against cancer-associated muc1
CA3258344A1 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. CHELETARIANS AND BIFUNCTIONAL CONJUGATES
TW202506190A (zh) 2023-04-05 2025-02-16 日商第一三共股份有限公司 利用抗ｍｕｃ１抗體－藥物結合物投予的藥劑低敏感性癌之治療方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) * 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
JP3698370B2 (ja) 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6465220B1 (en) * 1998-12-21 2002-10-15 Glycozym Aps Glycosylation using GalNac-T4 transferase
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
ATE290879T1 (de) 1999-08-18 2005-04-15 Altarex Medical Corp Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
ES2524442T3 (es) 2002-07-22 2014-12-09 Glycotope Gmbh Procedimiento para la producción de una mucina (MUC1) inmunoestimulante
DK1530628T3 (da) 2002-08-16 2011-01-10 Glycotope Gmbh Fremgangsmåde til fremstilling af temperaturinducerede tumorcellelysater til anvendelse som immunogene forbindelser
SI1654353T1 (sl) 2003-08-18 2013-09-30 Glycotope Gmbh Tumorski celični liniji NM-F9 (DSM ACC2606) in NM-D4 (DSM ACC2605), njihove uporabe
CN103627670B (zh) 2004-02-13 2016-12-21 格莱克托普有限公司 高活性糖蛋白加工条件及其有效生产方法
EP3539981A1 (en) 2006-09-10 2019-09-18 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060292643A1 (en) * 2003-01-23 2006-12-28 Steffen Goletz Recognition molecules for the treatment and detection of tumours

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DANIELCZYK A. et al, PankoMab: a potent new generation anti-tumour MUC1 antibody, Cancer Immunology, Immunotherapy, 2006, Vol. 55(11), pg. 1337-1347 *

Also Published As

Publication number Publication date
SG10201404019XA (en) 2014-09-26
CU23972B1 (es) 2013-12-27
WO2011012309A8 (en) 2011-04-07
AR077334A1 (es) 2011-08-17
KR20120051724A (ko) 2012-05-22
ZA201200166B (en) 2013-03-27
JP6272916B2 (ja) 2018-01-31
NZ597563A (en) 2013-08-30
CA2768888A1 (en) 2011-02-03
CN102574926A (zh) 2012-07-11
CN102574926B (zh) 2014-10-15
US9217038B2 (en) 2015-12-22
IL217827A0 (en) 2012-03-29
BR112012002226A2 (pt) 2016-11-08
CU20120019A7 (es) 2012-06-21
AU2010278302A1 (en) 2012-02-09
EA029954B1 (ru) 2018-06-29
US20120128676A1 (en) 2012-05-24
JP5922018B2 (ja) 2016-05-24
SG177527A1 (en) 2012-02-28
EP2281844A1 (en) 2011-02-09
CA2768888C (en) 2019-02-26
MX2012000874A (es) 2012-02-01
EA201270207A1 (ru) 2012-07-30
EP2459595A1 (en) 2012-06-06
WO2011012309A1 (en) 2011-02-03
IL217827A (en) 2017-05-29
JP2013500703A (ja) 2013-01-10
EP3421497A1 (en) 2019-01-02
KR101773506B1 (ko) 2017-08-31
JP2016041771A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
AU2010278302B2 (en) MUC1 antibodies
CN112601762B (zh) 抗cd47抗体及其应用
Wels et al. Construction, bacterial expression and characterization of a bifunctional single–chain antibody–phosphatase fusion protein targeted to the human ERBB–2 receptor
TWI708788B (zh) 雙特異性抗體
TWI719966B (zh) 結合ｃｄ４７之抗體治療劑
JP7533898B2 (ja) 血中半減期の向上のための抗体Ｆｃ変異体
EP4083072B1 (en) Muc1* antibodies
KR101477762B1 (ko) 특이성 결합 단백질 및 용도
CN112449641A (zh) 抗-muc1抗体
CN113480657B (zh) 针对her2的单域抗体及其衍生蛋白和应用
WO2012020059A1 (en) Humanized egfr antibodies
TWI714895B (zh) 抗csf-1r抗體、其抗原結合片段及其醫藥用途
WO2022075439A1 (ja) 抗トランスフェリンレセプター抗体の薬効又は感受性の判定方法
EP4613774A1 (en) Single domain antibody targeting human ror1
KR20250007549A (ko) Nk 세포종양 치료제
HK40082756A (en) Muc1* antibodies
CN119546636A (zh) FcRn-结合多肽及其用途
WO2025132836A1 (en) Antibodies against cd24
CN121449745A (zh) 靶向baff-r的全人源抗体
JP2025531360A (ja) 分離した抗原結合タンパク質及びその使用
CN119751684A (zh) 一种抗psma的抗原结合片段、抗体及其应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: DAIICHI SANKYO CO., LTD.

Free format text: FORMER OWNER(S): GLYCOTOPE GMBH